Skip to main content
SpringerLink
Log in

EMEA setzt die Zulassung von Raptiva für die Therapie der Psoriasis aus

Kommentar

The EMEA suspends approval of Raptiva for psoriasis

Commentary

  • In der Diskussion
  • Published:
Der Hautarzt Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. PRESS RELEASE (2009) European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). London, Doc. Ref. EMEA/CHMP/20857/2009

Download references

Interessenkonflikt

Keine Angaben.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie der Ludwig-Maximilians-Universität München, Frauenlobstraße 9–11, 80337, München, Deutschland

    J.C. Prinz

Authors
  1. J.C. Prinz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J.C. Prinz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prinz, J. EMEA setzt die Zulassung von Raptiva für die Therapie der Psoriasis aus. Hautarzt 60, 345–346 (2009). https://doi.org/10.1007/s00105-009-1743-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-009-1743-z

Search

Navigation